더바이오 10월 15일 주요뉴스 [https://www.thebionews.net/edit/webzine.html?idxno=663](https://www.thebionews.net/edit/webzine.html?idxno=663) ●“위고비 맞은 한국인, 체지방 15%↓…골격근 비율은 오히려 증가” [https://www.thebionews.net/news/articleView.html?idxno=29049](https://www.thebionews.net/news/articleView.html?idxno=29049) ●진양곤 HLB 의장 “리보세라닙, CRL 받아도 재도전…플랜 A부터 Z 준비” [https://www.thebionews.net/news/articleView.html?idxno=29093](https://www.thebionews.net/news/articleView.html?idxno=29093) ●美애로우헤드 ‘ARO-MAPT’, 알츠하이머 1·2a상서 타우 최대 85%↓ 확인 [https://www.thebionews.net/news/articleView.html?idxno=29052](https://www.thebionews.net/news/articleView.html?idxno=29052) ●中켈룬·MSD ‘TROP2 ADC’, 폐암·유방암 최종 OS 발표…자궁내막암 3상 첫 공개 [https://www.thebionews.net/news/articleView.html?idxno=29051](https://www.thebionews.net/news/articleView.html?idxno=29051) ●한미약품 “희귀질환 임상, 초기 설계부터 달라야”…6개 영역별 전략 제시 [https://www.thebionews.net/news/articleView.html?idxno=29083](https://www.thebionews.net/news/articleView.html?idxno=29083) ●알지노믹스, 대표 이어 임원진도 자사주 장내 매수 대열…“책임경영 강화” [https://www.thebionews.net/news/articleView.html?idxno=29087](https://www.thebionews.net/news/articleView.html?idxno=29087) ●아리바이오 “K바이오, 글로벌 3상 직접 하려면 전문성·임상운영·자금 필요” [https://www.thebionews.net/news/articleView.html?idxno=29080](https://www.thebionews.net/news/articleView.html?idxno=29080) ●HLB그룹, ‘그룹 IR 데이’ 개최…첫 FDA 승인 넘어 ‘지속 성장’ 전략 공개 [https://www.thebionews.net/news/articleView.html?idxno=29094](https://www.thebionews.net/news/articleView.html?idxno=29094) ●HLB이노베이션, 12월 미국혈액학회서 ‘SynKIR-310’ 1상 중간 결과 공개 [https://www.thebionews.net/news/articleView.html?idxno=29086](https://www.thebionews.net/news/articleView.html?idxno=29086) ●바이오엔테크·온코C4 ‘고티스토바트’, 폐암 3상서 OS 개선…18.5개월 [https://www.thebionews.net/news/articleView.html?idxno=29050](https://www.thebionews.net/news/articleView.html?idxno=29050) ●美 비어, 길리어드와 2.5조원 규모 계약…고형암 ‘이중 마스킹 TCE’ 3종 개발 [https://www.thebionews.net/news/articleView.html?idxno=29078](https://www.thebionews.net/news/articleView.html?idxno=29078) ●알보텍, ‘아일리아 8㎎’ 바이오시밀러 유럽 허가 신청…‘고용량’ 시장 공략 [https://www.thebionews.net/news/articleView.html?idxno=29077](https://www.thebionews.net/news/articleView.html?idxno=29077) ●지놈앤컴퍼니 “‘GEN-001’ 종양 축소 관찰…위암 병용임상 가능성↑” [https://www.thebionews.net/news/articleView.html?idxno=29048](https://www.thebionews.net/news/articleView.html?idxno=29048) ●佛 에노디아, 화이자와 6800억원 규모 라이선스 계약…‘Sec61 억제제’ 개발 [https://www.thebionews.net/news/articleView.html?idxno=29073](https://www.thebionews.net/news/articleView.html?idxno=29073) ●디앤디파마텍 “GLP-1 진화, 체중 감소 효능 넘어 편의성·적응증 확대로” [https://www.thebionews.net/news/articleView.html?idxno=29072](https://www.thebionews.net/news/articleView.html?idxno=29072) ●한국다이이찌산쿄, 최초 ACL 억제제 ‘넥스레톨’ 식품의약품안전처 허가 획득 [https://www.thebionews.net/news/articleView.html?idxno=29075](https://www.thebionews.net/news/articleView.html?idxno=29075) ●리가켐바이오, ADC Awards ‘최고 ADC 플랫폼’ 최고상 수상…8회 연속 수상 [https://www.thebionews.net/news/articleView.html?idxno=29074](https://www.thebionews.net/news/articleView.html?idxno=29074) ●MSD, ‘윈레브에어’ ESC/ERS 폐동맥고혈압 가이드라인 ‘강한 권고’ 등급 획득 [https://www.thebionews.net/news/articleView.html?idxno=29061](https://www.thebionews.net/news/articleView.html?idxno=29061) ●셀트리온, 유럽 최대 소화기학회서 ‘램시마SC’ 경쟁력 집중 조명 [https://www.thebionews.net/news/articleView.html?idxno=29057](https://www.thebionews.net/news/articleView.html?idxno=29057) ●KIMCo재단·연세대 바이오헬스기술지주·이크레더블 ‘바이오 커넥트’ 개최 [https://www.thebionews.net/news/articleView.html?idxno=29076](https://www.thebionews.net/news/articleView.html?idxno=29076) ●Dong-A ST launches Darbecron, a Darbepoetin-alpha biosimilar for anemia, in the UAE [https://www.thebionews.net/news/articleView.html?idxno=29092](https://www.thebionews.net/news/articleView.html?idxno=29092) ●HK inno.N presents U.S. Phase 3 results for new drug ‘K-CAB’ in non-erosive gastroesophageal reflux disease at ACG [https://www.thebionews.net/news/articleView.html?idxno=29090](https://www.thebionews.net/news/articleView.html?idxno=29090) ●KDDF CEO Park Yeong-min: “Korean biotech firms set to expand global cooperation, delivering substantial new drug development results” [https://www.thebionews.net/news/articleView.html?idxno=29089](https://www.thebionews.net/news/articleView.html?idxno=29089) ●Three major global pharma firms propose new drug development collaboration strategies: joint research, technology acquisition, and early-stage investment [https://www.thebionews.net/news/articleView.html?idxno=29088](https://www.thebionews.net/news/articleView.html?idxno=29088) ●Dongkook Pharmaceutical renames itself ‘DK Centellian’ after 44 years, launching full-scale global market expansion [https://www.thebionews.net/news/articleView.html?idxno=29084](https://www.thebionews.net/news/articleView.html?idxno=29084) ●L&C Bio inks USD 60 million exclusive ‘Re2O’ supply agreement with U.S.-based corporate & tissue bank [https://www.thebionews.net/news/articleView.html?idxno=29082](https://www.thebionews.net/news/articleView.html?idxno=29082) *제약바이오 10월 15일 아침 유튜브 라디오 뉴스(매일 아침 업로드) [https://www.youtube.com/watch?v=V5SUQta2Rmo](https://www.youtube.com/watch?v=V5SUQta2Rmo)